Demographic Characteristics of Incident Users of Selected Non-Insulin Antidiabetics in TriNetX: A Descriptive Analysis

In these analyses, we aimed to describe demographic characteristics of patients with an incident medication fact record for selected non-insulin antidiabetics in the TriNetX Live™ platform. We examined five categories of non-insulin antidiabetics, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose co-transporter 2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, 2nd Generation Sulfonylurea, and Metformin. Seven GLP-1 RAs were also examined, including albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide. The study period includes data from October 1, 2017 to September 30, 2023.

• Analysis 1: We ran this query on February 12, 2024. This query contains data from 80 health care organizations (HCOs) provided through the TriNetX Live™ platform in their USA Network, which includes HCOs that may implement date shifting between 0 and 365 days in either direction. 
• Analysis 2: We ran this query on May 14, 2024. This query contains data from 60 HCOs provided through the TriNetX Live™ platform in their USA Network Minimal Shift, which includes HCOs that may implement date shifting between 0 and 14 days in either direction. This includes all HCOs from the USA Network without date shifting.